Vonoprazan‐ vs proton‐pump inhibitor‐based first‐line 7‐day triple therapy for clarithromycin‐susceptible Helicobacter pylori: A multicenter, prospective, randomized trial

Background The eradication rate of vonoprazan‐based first‐line triple therapy (combined with clarithromycin and amoxicillin) (V‐AC) was reported to be 97.6% in patients with clarithromycin (CAM)‐susceptible Helicobacter pylori in a phase III study, whereas our real‐world, prospective, multicenter co...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Helicobacter (Cambridge, Mass.) Mass.), 2018-04, Vol.23 (2), p.e12456-n/a
Hauptverfasser:	Sue, Soichiro, Ogushi, Marina, Arima, Isao, Kuwashima, Hirofumi, Nakao, Satoshi, Naito, Makoto, Komatsu, Kazuo, Kaneko, Hiroaki, Tamura, Toshihide, Sasaki, Tomohiko, Kondo, Masaaki, Shibata, Wataru, Maeda, Shin
Format:	Artikel
Sprache:	eng
Schlagworte:	7‐day triple therapy Aged Amoxicillin Clarithromycin Clarithromycin - therapeutic use clarithromycin‐susceptible Confidence intervals Eradication Female Helicobacter Infections - drug therapy Helicobacter Infections - microbiology Helicobacter pylori Helicobacter pylori - drug effects Helicobacter pylori - pathogenicity Helicobacter pylori eradication Humans Infections Male Middle Aged Motivation Omeprazole Patients Proton pump inhibitors Proton Pump Inhibitors - therapeutic use Pyrroles - therapeutic use Sulfonamides - therapeutic use Therapy Urea vonoprazan
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background The eradication rate of vonoprazan‐based first‐line triple therapy (combined with clarithromycin and amoxicillin) (V‐AC) was reported to be 97.6% in patients with clarithromycin (CAM)‐susceptible Helicobacter pylori in a phase III study, whereas our real‐world, prospective, multicenter cohort study yielded an eradication rate
ISSN:	1083-4389 1523-5378
DOI:	10.1111/hel.12456